Evidence base for multimodal therapy in cachexia

Current Opinion in Supportive and Palliative Care

Volumn 6, Issue 4, 2012, Pages 424-431

  Solheim, Tora S ^a,b   Laird, Barry J A ^a,c  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cachexia; Cancer; Multimodal

Indexed keywords

ANTIINFLAMMATORY AGENT;

CACHEXIA; DIET; DIET SUPPLEMENTATION; EXERCISE; HUMAN; METHODOLOGY; MULTIMODALITY CANCER THERAPY; NEOPLASM; REVIEW;

ANTI-INFLAMMATORY AGENTS; CACHEXIA; COMBINED MODALITY THERAPY; DIET; DIETARY SUPPLEMENTS; EXERCISE; HUMANS; NEOPLASMS;

EID: 84871239574     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e328359b668     Document Type: Review

References (49)

1. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic nonsmall-cell lung cancer. N Engl J Med 2010; 363:733-742.
2. Skipworth RJ, Stewart GD, Dejong CH, et al. Pathophysiology of cancer cachexia: much more than host-tumour interaction? Clin Nutr 2007; 26:667-676.
3. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011; 12: 489-495.
4. Fearon KC, Preston T. Body composition in cancer cachexia. Infusions therapie 1990; 17 (Suppl 3):63-66.
5. Fearon KC. Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur J Cancer 2008; 44:1124-1132.
6. Yavuzsen T, Davis MP, Walsh D, et al. Systematic review of the treatment of cancer-Associated anorexia and weight loss. J Clin Oncol 2005; 23:8500-8511.
7. Maltoni M, Nanni O, Scarpi E, et al. High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials. Ann Oncol 2001; 12:289-300.
8. Berenstein EG, Ortiz Z. Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev 2005;CD004310.
9. Colomer R, Moreno-Nogueira JM, Garcia-Luna PP, et al. N-3 fatty acids, cancer and cachexia: a systematic review of the literature. Br J Nutr 2007; 97:823-831.
10. Dewey A, Baughan C, Dean T, et al. Eicosapentaenoic acid (EPA, anomega-3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database Syst Rev 2007;CD004597.
11. Mazzotta P, Jeney CM. Anorexia-cachexia syndrome: a systematic review of the role of dietary polyunsaturated fatty acids in the management of symptoms, survival, and quality of life. J Pain Symptom Manage 2009; 37:1069-1077.
12. Ries A, Trottenberg P, Elsner F, et al. A systematic review on the role of fish oil for the treatment of cachexia in advanced cancer: an EPCRC cachexia guidelines project. Palliat Med 2012; 26:294-304.
13. Murphy RA, Yeung E, Mazurak VC, Mourtzakis M. Influence of eicosapentaenoic acid supplementation on lean body mass in cancer cachexia. Br J Cancer 2011; 105:1469-1473.
14. Mantovani G, Maccio A, Madeddu C, et al. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist 2010; 15:200-211.
15. Awad S, Tan BH, Cui H, et al. Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clin Nutr 2012; 31:74-77.
16. Skipworth RJ, Stewart GD, Dejong CH, et al. Pathophysiology of cancer cachexia: much more than host-tumour interaction? Clin Nutr 2007; 26:667-676.
17. Conn VS, Hafdahl AR, Porock DC, et al. A meta-Analysis of exercise interventions among people treated for cancer. Support Care Cancer 2006; 14:699-712.
18. Schmitz KH, Holtzman J, Courneya KS, et al. Controlled physical activity trials in cancer survivors: a systematic review and meta-Analysis. Cancer Epidemiol Biomarkers Prev 2005; 14:1588-1595.
19. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature 2008; 451:1069-1075.
20. Lowe SS, Watanabe SM, Courneya KS. Physical activity as a supportive care intervention in palliative cancer patients: a systematic review. J Support Oncol 2009; 7:27-34.
21. Oldervoll LM, Loge JH, Lydersen S, et al. Physical exercise for cancer patients with advanced disease: a randomized controlled trial. Oncologist 2011; 16:1649-1657.
22. Lowe SS, Watanabe SM, Baracos VE, Courneya KS. Physical activity interests and preferences in palliative cancer patients. Support Care Cancer 2009; 10:10.
23. Bovio G, Bettaglio R, Bonetti G, et al. Evaluation of nutritional status and dietary intake in patients with advanced cancer on palliative care. Minerva Gastroenterol Dietol 2008; 54:243-250.
24. Hutton JL, Martin L, Field CJ, et al. Dietary patterns in patients with advanced cancer: implications for anorexia-cachexia therapy. Am J Clin Nutr 2006; 84:1163-1170.
25. Bosaeus I, Daneryd P, Svanberg E, Lundholm K. Dietary intake and resting energy expenditure in relation to weight loss in unselected cancer patients. Int J Cancer 2001; 93:380-383.
26. Koretz RL, Avenell A, Lipman TO, et al. Does enteral nutrition affect clinical outcome? A systematic review of the randomized trials. Am J Gastroenterol 2007; 102:412-429; quiz 68.
27. Koretz RL, Lipman TO, Klein S. AGA technical review on parenteral nutrition. Gastroenterology 2001; 121:970-1001.
28. Baldwin C, Weekes CE. Dietary advice for illness-related malnutrition in adults. Cochrane Database of Systematic Reviews 2008:CD002008.
29. Ravasco P, Monteiro-Grillo I, Vidal PM, Camilo ME. Dietary counseling improves patient outcomes: a prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy. J Clin Oncol 2005; 23:1431-1438.
30. Ravasco P, Monteiro-Grillo I, Marques Vidal P, Camilo ME. Impact of nutrition on outcome: a prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy. Head Neck 2005; 27:659-668.
31. Isenring EA, Capra S, Bauer JD. Nutrition intervention is beneficial in oncology outpatients receiving radiotherapy to the gastrointestinal or head and neck area. Br J Cancer 2004; 91:447-452.
32. Macia E, Moran J, Santos J, et al. Nutritional evaluation and dietetic care in cancer patients treated with radiotherapy: prospective study. Nutrition 1991; 7:205-209.
33. Lovik A, Almendingen K, Dotterud M, et al. Dietary information after radiotherapy of head and neck cancer. Tidsskr Nor Laegeforen 1996; 116:2303-2306.
34. Wallengren O, Lundholm K, Bosaeus I. Diet energy density and energy intake in palliative care cancer patients. Clin Nutr 2005; 24:266-273.
35. McMillan DC, O'Gorman P, Fearon KC, McArdle CS. A pilot study of megestrol acetate and ibuprofen in the treatment of cachexia in gastrointestinal cancer patients. Br J Cancer 1997; 76:788-790.
36. Daneryd P, Svanberg E, Korner U, et al. Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: a randomized prospective study. Cancer Res 1998; 58:5374-5379.
37. McMillan DC, Wigmore SJ, Fearon KC, et al. A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br J Cancer 1999; 79:495-500.
38. Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-Associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 2002; 20:567-573.
39. Cerchietti LC, Navigante AH, Peluffo GD, et al. Effects of celecoxib, medrox-yprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: a pilot study. J Pain Symptom Manage 2004; 27:85-95.
40. Jatoi A, Rowland K, Loprinzi CL, et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-Associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol 2004; 22:2469-2476.
41. Mantovani G, Maccio A, Madeddu C, et al. A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progesta-gen, and anticyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress. Cancer Epidemiol Biomarkers Prev 2006; 15:1030-1034.
42. Cerchietti LC, Navigante AH, Castro MA. Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer. Nutr Cancer 2007; 59:14-20.
43. Lundholm K, Daneryd P, Bosaeus I, et al. Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease: effects on survival, metabolism, and function. Cancer 2004; 100:1967-1977.
44. Lundholm K, Korner U, Gunnebo L, et al. Insulin treatment in cancer cachexia: effects on survival, metabolism, and physical functioning. Clin Cancer Res 2007; 13:2699-2706.
45. Madeddu C, Dessi M, Panzone F, et al. Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib +/\megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. Clin Nutr 2012; 31:176-182.
46. Maccio A, Madeddu C, Gramignano G, et al. A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life. Gynecol Oncol 2012; 124:417-425.
47. Macdonald N. Terminology in cancer cachexia: importance and status. Curr Opin Clin Nutr Metab Care 2012; 15:220-225.
48. Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980; 69:491-497.
49. Rogers ES, MacLeod RD, Stewart J, et al. A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), resistance training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients: ACCeRT study. BMC Cancer 2011; 11:493.